Medicinal chemistry of anticancer drugs:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Amsterdam [u.a.]
Elsevier
2008
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index. - Formerly CIP |
| Beschreibung: | XV, 442 S. Ill. |
| ISBN: | 9780444528247 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV023481424 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 080807s2008 a||| |||| 00||| eng d | ||
| 020 | |a 9780444528247 |c £100.00 : £100.00 |9 978-0-444-52824-7 | ||
| 035 | |a (OCoLC)254427997 | ||
| 035 | |a (DE-599)BSZ28267375X | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 082 | 0 | |a 616.994061 | |
| 084 | |a VS 9100 |0 (DE-625)147725:253 |2 rvk | ||
| 100 | 1 | |a Avendaño, Carmen |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Medicinal chemistry of anticancer drugs |c Carmen Avendaño and J. Carlos Menéndez |
| 264 | 1 | |a Amsterdam [u.a.] |b Elsevier |c 2008 | |
| 300 | |a XV, 442 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index. - Formerly CIP | ||
| 650 | 4 | |a Cancer - Chemotherapy | |
| 650 | 4 | |a Drugs - Design | |
| 650 | 4 | |a Pharmaceutical chemistry | |
| 650 | 4 | |a Cancer / Chemotherapy | |
| 650 | 4 | |a Drugs / Design | |
| 650 | 4 | |a Pharmaceutical chemistry | |
| 700 | 1 | |a Menéndez, José Carlos |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016663547&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016663547 | ||
Datensatz im Suchindex
| _version_ | 1804137907779272705 |
|---|---|
| adam_text | Preface ix
Abbreviations xi
1. Introduction 1
1. Some General Remarks About Cancer and Cancer Chemotherapy 1
2. A Brief Account of the Role of Chemistry in Cancer Chemotherapy 3
3. Natural Products in Cancer Chemotherapy 5
4. A Brief Comment About Cancer Nanotechnology 6
5. Conclusion 7
References 7
2. Antimetabolites 9
1. Introduction 10
2. Inhibitors of the Biosynthesis of Uridylic Acid 10
1 Inhibitors of the Biosynthesis of 2 -Deoxyribonucleotides by
Ribonucleotide Reductase (RNR) 11
4. Inhibitors of the Biosynthesis of Thymidilic Acid 18
5. Inhibitors of Dihydrofolate Reductase (DHFR) 32
6. Inhibitors of the De Novo Purine Biosynthesis Pathway 36
7. Inhibitors of Adenosine Deaminase 42
8. Inhibitors of Late Stages in DNA Synthesis 45
9. Antimetabolite Enzymes 50
References 51
3. Anticancer Drugs That Inhibit Hormone Action 53
1. .Introduction 54
2. Estrogens and Their Involvement in Carcinogenesis 54
3. Antiestrogens as Antitumor Drugs 58
4. Aromatase Inhibitors 65
•5.- Steroid Sulfatase Inhibitors 73
6: Androgen-Related Antitumor Agents 75
7. Regulation of Steroidal Hormone Synthesis as a Target for Antitumor Drugs 79
8. Miscellaneous Steroid Hormone-Related Anticancer Therapy 85
9. Compounds Acting on Other Proteins of the Nuclear Receptor Superfamily:
Retinoids 86
References 90
v
vi Contents
4. Anticancer Drugs Acting via Radical Species, Photosensitiiers and
Photodynamic Therapy of Cancer 93
1. Introduction: Radicals and Other Reactive Oxygen Species 93
2. Biological Effects of ROS 95
3. Anthracyclines and Their Analogs 102
4. Mitoxantrone and Related Quinones 112
5. Actinomycin D 114
6. Chartreusin, Elsamicin A, and Related Compounds 116
7. Bleomycins 116
8. Enediyne Antibiotics 122
9. Tirapazamine 126
10. Penclomedine 128
11. Radiosensitizers 129
12. Photodynamic Therapy of Cancer 132
References 135
5. DNA Alkylating Agents 139
1. Introduction 139
2. Nitrogen Mustards 141
3. Aziridines (Ethyleneimines) 154
4. Epoxides 158
5. Methanesulfonates 159
6. Nitrosoureas 160
7. Triazenes 165
8. Methylhydrazines 166
9. 1,3,5-Triazines: Hexamethylmelamine and Trimelamol 168
10. Platinum Complexes 169
11. Miscellaneous Alkylating and Acylating Antitumor Agents 173
References 174
6. Alkylating and Non-Alkylating Compounds Interacting with the
DNA Minor Groove 177
1. Introduction 177
2. Netropsin, Distamycin, and Related Compounds 178
3. Mitomycins 182
4. Tetrahydroisoquinoline Alkaloids 189
5. Cyclopropylindole Alkylating Agents 193
6. Pyrrolo[l,4]Benzodiazepines 195
References 196
7. DNA Intercalators and Topoisomerase Inhibitors 199
1. DNA Intercalation and Its Consequences 200
2. Monofunctional Intercalating Agents 201
3. Bifunctional Intercalating Agents 206
4. DNA Topoisomerases 209
Contents vii
5. Topoisomerase II Poisons 213
6. Topoisomerase II Catalytic Inhibitors 218
7. Specific Topoisomerase I Inhibitors 220
References 225
8. Anticancer Drugs Targeting Tubulin and Microtubules 229
1. Introduction 229
2. Drugs That Inhibit Microtubule Polymerization at High Concentrations 231
3. Microtubule-Stabilizing Agents: Compounds Binding at the Taxane Site 237
4. Miscellaneous Anticancer Drugs Acting on Novel Sites on Tubuline 245
5. Antivascular Effects of Microtubule-Targeted Agents 245
6. Mitotic Kinesin Inhibitors 246
References 247
9. Drugs That Inhibit Signalling Pathways for Tumor Cell
Growth and Proliferation 251
1. Introduction: The Role of Protein Kinases in Cancer 252
2. Signalling Pathways Related to Kinases 254
3. Inhibitors of Tyrosine Kinases (TKs) 254
4. Inhibitors of Serine-Threonine Kinases 275
5. Inhibitors of the RAS-RAF-MEK Signalling Pathway and Farnesyl Transferase 286
6. Inhibitors of Farnesyldiphosphate Synthase and Geranylgeranyldiphosphate
Synthase 295
7. Anticancer Drugs Acting on Apoptotic Signalling Pathways 296
8. Inhibitors of Heat-Shock Proteins (HSP 90) 299
References 302
10. Other Approaches to Targeted Therapy 307
1. Proteasome Inhibitors 307
2. Antiangiogenic Agents Unrelated to Kinase Signaling 312
3. Epigenetic Therapy of Cancer 323
4. Inhibitors of Other DNA-Associated Enzymes 337
5. Therapy Directed at Other Targets 341
References 347
11. Drug Targeting in Anticancer Chemotherapy 351
1. Introduction 351
2. Prodrug-Based Anticancer Drug Targeting: Small-Molecule Prodrugs 352
3. Polymer-Protein Conjugates 368
4. Macromolecular Small-Drug Carrier Systems 369
5. Polymer-Directed Enzyme Prodrug Therapy (PDEPT) 377
6. Folate Receptor-Targeted Chemotherapy and Immunotherapy of Cancer 378
7. Liposomes and Nanoparticles in Anticancer Drug Targeting 380
References 383
viii Contents
12. Drugs That Modulate Resistance to Antitumor Agents 387
1. ATP-Binding Cassette Efflux Pumps in Anticancer Drug Resistance 388
2. Glutathione and Glutathione-5-Transferase in Anticancer Drug Resistance 397
3. Chemosensitizers Targeting DNA-Repair Systems 401
4. Antitumor Drug Resistance Related to Extracellular pH: Tumor-Associated
Carbonic Anhydrase as an Anticancer Target 412
References 414
13. Cancer Chemoprevention 417
1. Introduction 417
2. Ligands for Nuclear Receptors in Cancer Chemoprevention 418
3. Anti-Inflammatory Agents and Antioxidants in Cancer Chemoprevention 421
4. Chromatin Modifiers in Cancer Chemoprevention 425
5. Miscellaneous Agents for Chemoprevention 426
6. Cancer Vaccines 428
References 428
Index 431
|
| adam_txt |
Preface ix
Abbreviations xi
1. Introduction 1
1. Some General Remarks About Cancer and Cancer Chemotherapy 1
2. A Brief Account of the Role of Chemistry in Cancer Chemotherapy 3
3. Natural Products in Cancer Chemotherapy 5
4. A Brief Comment About Cancer Nanotechnology 6
5. Conclusion 7
References 7
2. Antimetabolites 9
1. Introduction 10
2. Inhibitors of the Biosynthesis of Uridylic Acid 10
1 Inhibitors of the Biosynthesis of 2'-Deoxyribonucleotides by
Ribonucleotide Reductase (RNR) 11
4. Inhibitors of the Biosynthesis of Thymidilic Acid 18
5. Inhibitors of Dihydrofolate Reductase (DHFR) 32
6. Inhibitors of the De Novo Purine Biosynthesis Pathway 36
7. Inhibitors of Adenosine Deaminase 42
8. Inhibitors of Late Stages in DNA Synthesis 45
9. Antimetabolite Enzymes 50
References ' 51
3. Anticancer Drugs That Inhibit Hormone Action 53
1. .Introduction 54
2. Estrogens and Their Involvement in Carcinogenesis 54
3. Antiestrogens as Antitumor Drugs 58
4. Aromatase Inhibitors 65
•5.- 'Steroid Sulfatase Inhibitors 73
6: Androgen-Related Antitumor Agents 75
7. Regulation of Steroidal Hormone Synthesis as a Target for Antitumor Drugs 79
8. Miscellaneous Steroid Hormone-Related Anticancer Therapy 85
9. Compounds Acting on Other Proteins of the Nuclear Receptor Superfamily:
Retinoids 86
References 90
v
vi Contents
4. Anticancer Drugs Acting via Radical Species, Photosensitiiers and
Photodynamic Therapy of Cancer 93
1. Introduction: Radicals and Other Reactive Oxygen Species 93
2. Biological Effects of ROS 95
3. Anthracyclines and Their Analogs 102
4. Mitoxantrone and Related Quinones 112
5. Actinomycin D 114
6. Chartreusin, Elsamicin A, and Related Compounds 116
7. Bleomycins 116
8. Enediyne Antibiotics 122
9. Tirapazamine 126
10. Penclomedine 128
11. Radiosensitizers 129
12. Photodynamic Therapy of Cancer 132
References 135
5. DNA Alkylating Agents 139
1. Introduction 139
2. Nitrogen Mustards 141
3. Aziridines (Ethyleneimines) 154
4. Epoxides 158
5. Methanesulfonates 159
6. Nitrosoureas 160
7. Triazenes 165
8. Methylhydrazines 166
9. 1,3,5-Triazines: Hexamethylmelamine and Trimelamol 168
10. Platinum Complexes 169
11. Miscellaneous Alkylating and Acylating Antitumor Agents 173
References 174
6. Alkylating and Non-Alkylating Compounds Interacting with the
DNA Minor Groove 177
1. Introduction 177
2. Netropsin, Distamycin, and Related Compounds 178
3. Mitomycins 182
4. Tetrahydroisoquinoline Alkaloids 189
5. Cyclopropylindole Alkylating Agents 193
6. Pyrrolo[l,4]Benzodiazepines 195
References 196
7. DNA Intercalators and Topoisomerase Inhibitors 199
1. DNA Intercalation and Its Consequences 200
2. Monofunctional Intercalating Agents 201
3. Bifunctional Intercalating Agents 206
4. DNA Topoisomerases 209
Contents vii
5. Topoisomerase II Poisons 213
6. Topoisomerase II Catalytic Inhibitors 218
7. Specific Topoisomerase I Inhibitors 220
References 225
8. Anticancer Drugs Targeting Tubulin and Microtubules 229
1. Introduction 229
2. Drugs That Inhibit Microtubule Polymerization at High Concentrations 231
3. Microtubule-Stabilizing Agents: Compounds Binding at the Taxane Site 237
4. Miscellaneous Anticancer Drugs Acting on Novel Sites on Tubuline 245
5. Antivascular Effects of Microtubule-Targeted Agents 245
6. Mitotic Kinesin Inhibitors 246
References 247
9. Drugs That Inhibit Signalling Pathways for Tumor Cell
Growth and Proliferation 251
1. Introduction: The Role of Protein Kinases in Cancer 252
2. Signalling Pathways Related to Kinases 254
3. Inhibitors of Tyrosine Kinases (TKs) 254
4. Inhibitors of Serine-Threonine Kinases 275
5. Inhibitors of the RAS-RAF-MEK Signalling Pathway and Farnesyl Transferase 286
6. Inhibitors of Farnesyldiphosphate Synthase and Geranylgeranyldiphosphate
Synthase 295
7. Anticancer Drugs Acting on Apoptotic Signalling Pathways 296
8. Inhibitors of Heat-Shock Proteins (HSP 90) 299
References 302
10. Other Approaches to Targeted Therapy 307
1. Proteasome Inhibitors 307
2. Antiangiogenic Agents Unrelated to Kinase Signaling 312
3. Epigenetic Therapy of Cancer 323
4. Inhibitors of Other DNA-Associated Enzymes 337
5. Therapy Directed at Other Targets 341
References 347
11. Drug Targeting in Anticancer Chemotherapy 351
1. Introduction 351
2. Prodrug-Based Anticancer Drug Targeting: Small-Molecule Prodrugs 352
3. Polymer-Protein Conjugates 368
4. Macromolecular Small-Drug Carrier Systems 369
5. Polymer-Directed Enzyme Prodrug Therapy (PDEPT) 377
6. Folate Receptor-Targeted Chemotherapy and Immunotherapy of Cancer 378
7. Liposomes and Nanoparticles in Anticancer Drug Targeting 380
References 383
viii Contents
12. Drugs That Modulate Resistance to Antitumor Agents 387
1. ATP-Binding Cassette Efflux Pumps in Anticancer Drug Resistance 388
2. Glutathione and Glutathione-5-Transferase in Anticancer Drug Resistance 397
3. Chemosensitizers Targeting DNA-Repair Systems 401
4. Antitumor Drug Resistance Related to Extracellular pH: Tumor-Associated
Carbonic Anhydrase as an Anticancer Target 412
References 414
13. Cancer Chemoprevention 417
1. Introduction 417
2. Ligands for Nuclear Receptors in Cancer Chemoprevention 418
3. Anti-Inflammatory Agents and Antioxidants in Cancer Chemoprevention 421
4. Chromatin Modifiers in Cancer Chemoprevention 425
5. Miscellaneous Agents for Chemoprevention 426
6. Cancer Vaccines 428
References 428
Index 431 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Avendaño, Carmen Menéndez, José Carlos |
| author_facet | Avendaño, Carmen Menéndez, José Carlos |
| author_role | aut aut |
| author_sort | Avendaño, Carmen |
| author_variant | c a ca j c m jc jcm |
| building | Verbundindex |
| bvnumber | BV023481424 |
| classification_rvk | VS 9100 |
| ctrlnum | (OCoLC)254427997 (DE-599)BSZ28267375X |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| discipline_str_mv | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01424nam a2200385 c 4500</leader><controlfield tag="001">BV023481424</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080807s2008 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780444528247</subfield><subfield code="c">£100.00 : £100.00</subfield><subfield code="9">978-0-444-52824-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)254427997</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ28267375X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9100</subfield><subfield code="0">(DE-625)147725:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Avendaño, Carmen</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Medicinal chemistry of anticancer drugs</subfield><subfield code="c">Carmen Avendaño and J. Carlos Menéndez</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam [u.a.]</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV, 442 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index. - Formerly CIP</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer - Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs - Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical chemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer / Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical chemistry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Menéndez, José Carlos</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016663547&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016663547</subfield></datafield></record></collection> |
| id | DE-604.BV023481424 |
| illustrated | Illustrated |
| index_date | 2024-07-02T21:38:05Z |
| indexdate | 2024-07-09T21:19:45Z |
| institution | BVB |
| isbn | 9780444528247 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016663547 |
| oclc_num | 254427997 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | XV, 442 S. Ill. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Elsevier |
| record_format | marc |
| spelling | Avendaño, Carmen Verfasser aut Medicinal chemistry of anticancer drugs Carmen Avendaño and J. Carlos Menéndez Amsterdam [u.a.] Elsevier 2008 XV, 442 S. Ill. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index. - Formerly CIP Cancer - Chemotherapy Drugs - Design Pharmaceutical chemistry Cancer / Chemotherapy Drugs / Design Menéndez, José Carlos Verfasser aut HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016663547&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Avendaño, Carmen Menéndez, José Carlos Medicinal chemistry of anticancer drugs Cancer - Chemotherapy Drugs - Design Pharmaceutical chemistry Cancer / Chemotherapy Drugs / Design |
| title | Medicinal chemistry of anticancer drugs |
| title_auth | Medicinal chemistry of anticancer drugs |
| title_exact_search | Medicinal chemistry of anticancer drugs |
| title_exact_search_txtP | Medicinal chemistry of anticancer drugs |
| title_full | Medicinal chemistry of anticancer drugs Carmen Avendaño and J. Carlos Menéndez |
| title_fullStr | Medicinal chemistry of anticancer drugs Carmen Avendaño and J. Carlos Menéndez |
| title_full_unstemmed | Medicinal chemistry of anticancer drugs Carmen Avendaño and J. Carlos Menéndez |
| title_short | Medicinal chemistry of anticancer drugs |
| title_sort | medicinal chemistry of anticancer drugs |
| topic | Cancer - Chemotherapy Drugs - Design Pharmaceutical chemistry Cancer / Chemotherapy Drugs / Design |
| topic_facet | Cancer - Chemotherapy Drugs - Design Pharmaceutical chemistry Cancer / Chemotherapy Drugs / Design |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016663547&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT avendanocarmen medicinalchemistryofanticancerdrugs AT menendezjosecarlos medicinalchemistryofanticancerdrugs |